A Randomized, Double-blind, Placebo-controlled, Titration Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Single Dose and Escalating Doses of RO5095932 Administered Weekly in 4-weeks in Patients With Type 2 Diabetes Mellitus on Stable Metformin and Exenatide therapy.
Phase of Trial: Phase I
Latest Information Update: 10 Mar 2016
At a glance
- Drugs RO 5095932 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors Roche
- 07 Jun 2017 Biomarkers information updated
- 19 Sep 2011 Actual end date (August 2011) added as reported by ClinicalTrials.gov.
- 19 Sep 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.